Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

被引：3
|
作者：
Karimi, Leena [1 ]
Alves, Carla L. [1 ]
Terp, Mikkel G. [1 ]
Tuttolomondo, Martina [1 ]
Portman, Neil [2 ,3 ]
Ehmsen, Sidse [1 ,4 ]
Johansen, Lene E. [1 ]
Bak, Martin [5 ]
Lim, Elgene [2 ,3 ]
Ditzel, Henrik J. [1 ,6 ,7 ]
机构：
[1] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense, Denmark
[2] Garvan Inst Med Res, Sydney, NSW, Australia
[3] Univ New South Wales Sydney, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia
[4] Odense Univ Hosp, Inst Clin Res, Dept Oncol, Odense, Denmark
[5] Sydvestjysk Sygehus, Dept Pathol, Esbjerg, Denmark
[6] Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark
[7] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense, Denmark
来源：
CANCER COMMUNICATIONS | 2023年 / 43卷 / 06期
关键词：
PLUS FULVESTRANT; MONARCH; 2; ABEMACICLIB; ALPELISIB;
D O I：
10.1002/cac2.12425
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 725
页数：6
相关论文
共 50 条
  • [41] The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell Lymphoma
    Pal, Dhananjaya
    Arditti, Page Mangum
    Maddeboina, Krishnaiah
    McHale, Cody C.
    Yang, Hsih-Te
    Yada, Bharath
    Dryden, Hailey Lynn
    Foureau, David M.
    Durden, Donald L.
    BLOOD, 2023, 142
  • [42] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [43] PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients
    Del Re, Marzia
    Crucitta, Stefania
    Lorenzini, Giulia
    De Angelis, Claudia
    Diodati, Lucrezia
    Cavallero, Diletta
    Bargagna, Irene
    Cinacchi, Paola
    Fratini, Beatrice
    Salvadori, Barbara
    Ghilli, Matteo
    Roncella, Manuela
    Fontana, Andrea
    Danesi, Romano
    Cucchiara, Federico
    PHARMACOLOGICAL RESEARCH, 2021, 163
  • [44] Translational Highlights in Breast and Ovarian Cancer 2019-Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
    Hartkopf, Andreas D.
    Mueller, Volkmar
    Woeckel, Achim
    Lux, Michael P.
    Janni, Wolfgang
    Ettl, Johannes
    Belleville, Erik
    Schuetz, Florian
    Fasching, Peter A.
    Kolberg, Hans-Christian
    Welslau, Manfred
    Overkamp, Friedrich
    Taran, Florin-Andrei
    Brucker, Sara Y.
    Wallwiener, Markus
    Tesch, Hans
    Fehm, Tanja N.
    Schneeweiss, Andreas
    Lueftner, Diana
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1309 - 1319
  • [45] Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
    Lukoseviciute, Monika
    Maier, Henrietta
    Poulou-Sidiropoulou, Eleni
    Rosendahl, Erika
    Holzhauser, Stefan
    Dalianis, Tina
    Kostopoulou, Ourania N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Inhibition of CDK4/6 and Pi3Kγ modulates mammary tumor immune microenvironment to enhance response to immunotherapy
    Mont, Stacey
    Black, Kevin
    Chen, Sheau-Chiann
    Ayers, Gregory D.
    Richmond, Ann
    Vilgelm, Anna E.
    CANCER RESEARCH, 2018, 78 (13)
  • [47] DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Nanda, Sarmistha
    Shea, Martin J.
    Schiff, Rachel
    Osborne, C. Kent
    Rimawi, Mothaffar
    Fu, Xiaoyong
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Q901, a selective CDK7 inhibitor, a potential new strategy for primary and CDK4/6 inhibitor resistant ER-positive breast cancer
    Yu, Donghoon
    Jeon, Yeejin
    Park, Dongsik
    Seo, Mooyoung
    Ahn, Wongyun
    Kim, Jaeseung
    Nam, Kiyean
    CANCER RESEARCH, 2021, 81 (13)
  • [49] Combined aromatase, CDK4/6 and PI3K blockade using letrozole/ abemaciclib/LY3023414 in endometrial cancer
    Konstantinopoulos, Panagiotis A.
    Xiong, Niya
    Krasner, Carolyn
    Liu, Joyce F.
    Sawyer, Hannah
    Polak, Madeline
    Needham, Hope
    Geddes, Megan
    Koppermann, Lani
    Shea, Meghan
    Castro, Cesar
    Cheng, Su-Chun
    Matulonis, Ursula A.
    Lee, Elizabeth K.
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 52
  • [50] Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
    Bonelli, Mara
    Terenziani, Rita
    Zoppi, Silvia
    Fumarola, Claudia
    La Monica, Silvia
    Cretella, Daniele
    Alfieri, Roberta
    Cavazzoni, Andrea
    Digiacomo, Graziana
    Galetti, Maricla
    Petronini, Pier Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (14) : 1 - 16
12345